Vir Biotechnology vs. Sorrento Therapeutics: The Wisdom of Crowds Says...

By newsfeedback@fool.com (Adria Cimino)5 days ago

AD

Examining a company's general health and earnings prospects is a great way of predicting whether it could be a future stock market winner. But we don't have to stop there. We also can look around to see how other smart investors view our stock of interest.

How to do that? By playing Motley Fool CAPS. It's a stock-picking game that uses the wisdom of crowds to find the best investments. Players predict how stocks will perform versus the S&P 500 Index over a particular time frame. CAPS then rates players based on their performance compared to others. It also rates stocks according to the number of players who are bullish on them. Importantly, the game weighs more heavily the opinions of highly rated players. Motley Fool CAPS is fun -- and it can help you take advantage of the wisdom of crowds as you build and expand your portfolio. Let's use this game to help us choose the next winning coronavirus stock.

Image source: Getty Images.

Vir Biotechnology

CAPS rating: 1 out of 5 stars

What investors might be noticing: Vir Biotechnology (NASDAQ:VIR) and its big pharma partner, GlaxoSmithKline, recently requested an emergency use authorization (EUA) from the Food and Drug Administration for their investigational monoclonal antibody treatment for mild-to-moderate COVID-19. An independent committee monitoring the trial stopped enrollment in it early, citing the treatment's “profound efficacy.“

Continue read on fool.com